Not finding it? Sign in to also search OpenAlex live.
-
Second-Line Bosutinib Is Effective and Feasible in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) - an Analysis of a Subcohort of the Bodo Trial (CML-VII-study of the German CML Study Group)
Susanne Isfort, Kirsi Marjaana Manz, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +18 more
0citations -
Health-Related Quality of Life of CML Patients Under 2nd or 3rd Line Bosutinib Is Not Impaired Significantly By Gastrointestinal Toxicity (GI Tox) but Influenced By Sex - Results from a Subanalysis of the Bosutinib Dose Optimization (BODO) Study (CML-VII) Trial of the German CML Study Group
Susanne Isfort, Dominik Georg Friedrich Wolf, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +11 more
1citations -
Mindfulness-based cognitive group therapy for treatment-refractory anxiety disorder: A pragmatic randomized controlled trial2022 Journal of Anxiety Disorders article Psychology Mindfulness and Compassion Interventions Open access
Philip Spinhoven, Elena Hoogerwerf, Anne van Giezen, Anja Greeven
21citations -
Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study
Hareth Nahi, Saad Z. Usmani, María‐Victoria Mateos, Niels W.C.J. van de Donk, Philippe Moreau, Albert Oriol, +8 more
2citations -
P17.24.B BEVACIZUMAB VERSUS DEXAMETHASONE AS FIRST-LINE TREATMENT FOR SYMPTOMATIC CEREBRAL RADIATION NECROSIS AFTER RADIATION OF HIGH GRADE GLIOMA OR BRAIN METASTASES: A RANDOMIZED CLINICAL TRIAL
Edith M.T. Dieleman, Vera C. Keil, Marit van Barreveld, Marcel G.W. Dijkgraaf, L Topff, Sander N Wagemakers, +6 more
0citations -
A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)2022 Therapeutic Advances in Medical Oncology article Medicine Gastric Cancer Management and Outcomes Open access
Charlotte I. Stroes, Sandor Schokker, Mohammed Khurshed, Stephanie O. van der Woude, Ron A. A. Mathôt, Marije Slingerland, +15 more
6citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Ruben A. Mesa, Rami S. Komrokji, Steffen Koschmieder, +10 more
8citations -
Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.2020 Journal of Clinical Oncology conference-abstract Medicine Multiple Myeloma Research and Treatments Open access cited by 5 patents
Hareth Nahi, María‐Victoria Mateos, Niels W.C.J. van de Donk, Philippe Moreau, Albert Oriol, Torben Plesner, +7 more
2citations -
P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +11 more
1citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
1citations -
Aberrant intra‐epithelial lymphocytes cause enterocyte cell death in refractory celiac disease by CD103 ‐β7‐receptor‐mediated granzyme‐B degranulation which can be restored by etrolizumab2026 Clinical & Translational Immunology article Medicine Celiac Disease Research and Management Open access
Daan A R Castelijn, Jolanda MW van de Water, Laura R. de Baaij, Bridget S McGlinchy, Michelle van Leeuwen, Sander P.J. Joosten, +13 more
1citations -
Abstract CT194: Low-dose Interferon-alpha pre-conditioning and adoptive cell therapy in metastatic melanoma patients refractory to standard (immune) therapies - a phase 1/2 study
Monique K. van der Kooij, Els M.E. Verdegaal, Marten Visser, Carolien E. van der Minne, Linda de Bruin, Pauline Meij, +8 more
0citations -
Germ line LCP1 mutations cause immunodeficiency with neutropenia, monocytopenia, lymphopenia, and defective cytokinesis2025 Blood Advances article Biochemistry, Genetics and Molecular Biology Blood disorders and treatments Open access
Thijs van Bergen, Dennis A. Bosch, Christine Bellanné‐Chantelot, Roger Mulet‐Lazaro, Jacob R. Bledsoe, Lanpeng Chen, +21 more
4citations -
Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Meletios Athanasios Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksaç, Eirini Katodritou, +17 more
51citations